<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907436</url>
  </required_header>
  <id_info>
    <org_study_id>2018-4521</org_study_id>
    <secondary_id>18-30</secondary_id>
    <nct_id>NCT03907436</nct_id>
  </id_info>
  <brief_title>The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase</brief_title>
  <acronym>NUTRIENT</acronym>
  <official_title>The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MPN patient are able to adhere to a dietary
      intervention. Participants will be randomized to one of two healthy diets. Participants will
      receive in person dietician counseling and online curriculum. Adherence will be measured
      using online surveys and phone diet recalls. Changes in inflammatory markers in blood will
      also be measured at 5 time points during this 15 week study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 15 week study, including 10 weeks of active diet intervention. Each participant
      will receive one dietician counseling session at the beginning of the diet intervention
      period, two brief follow up dietician phone calls, and 10 diet education handouts delivered
      via email each week. The main objective of this protocol is to test whether MPN patients can
      adhere to a diet intervention. The investigators will measure adherence in both arms with
      patient reported diet recall every two weeks via internet surveys. As exploratory endpoints
      the investigators will measure changes in inflammatory markers, symptom burden, physical
      activity level, sleep, and gut microbiome in participants over the course of the study. If
      successful, the investigators plan to use this intervention in a larger trial to assess
      whether a diet intervention can effectively change symptom burden and inflammation in MPN
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to one of two healthy diets (USDA or Mediterranean diet)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not be told which diet arm they are randomized to. Participants will not be told the two options are USDA or Mediterranean, only there are two &quot;healthy&quot; diets.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>14-point Mediterranean Diet Adherence Screener (MEDAS)</measure>
    <time_frame>15 weeks</time_frame>
    <description>14 question survey assessing adherence to a Mediterranean diet. This is a 14 question survey, with possible 1 point per question. A perfect adherence to a Mediterranean Diet is 14 on this survey (min 0 max 14). Higher values represent closer adherence to a Mediterranean diet.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)</measure>
    <time_frame>15 weeks</time_frame>
    <description>MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score, a validated measure for quantifying symptom burden in MPN. This is a 10 item survey, with each question answered on a scale of 0 to 10. The minimum score is 0, the maximum score is 100. Higher numbers mean a higher symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines</measure>
    <time_frame>15 weeks</time_frame>
    <description>Measurement of inflammatory cytokines in the plasma. This includes EGF, Eotaxin, FGF-basic, G-CSF, GM-CSF, HGF, IFN-alpha, IFN-gamma, IL-1 beta, IL-1 alpha, IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40/p70) IL-13, IL-15, IL-17A, IL-17F, IL-22, IP-10, MCP-1, MIG, MIP-1 alpha, MIP-1 beta, RANTES, TNF-alpha, VEGF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>USDA diet arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mediterranean diet arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>USDA Diet</intervention_name>
    <description>Participants will receive counseling and education on USDA Guidelines for Americans, 2010</description>
    <arm_group_label>USDA diet arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Participants will receive counseling and education on a Mediterranean diet.</description>
    <arm_group_label>Mediterranean diet arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Diagnosis of Myeloproliferative Neoplasm (MPN) including Essential Thrombocythemia
             (ET), Polycythemia Vera (PV), or Myelofibrosis (MF)

          -  Any type of previous therapy is allowed

          -  ECOG performance status â‰¤2

          -  Life expectancy of greater than 20 weeks

          -  Has an email address and can access the internet

          -  Able to read and understand English

        Exclusion Criteria:

          -  Children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela G Fleischman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.wearempn.org/interestedinenrolling</url>
    <description>website with more information on the diet and enrollment information</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Angela G. Fleischman</investigator_full_name>
    <investigator_title>Assistant Professor, Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>nutrition</keyword>
  <keyword>diet</keyword>
  <keyword>inflammation</keyword>
  <keyword>myeloproliferative neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03907436/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

